Table 6. Review of Previous Studies of GPS as a Prognostic Factor for Advanced NSCLC [16, 29-34].
| Author (year) | Country | N | Patient treatment | Variables | OS |
PFS |
||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||||
| Forrest et al (2004) [29] | UK | 109 | Inoperable, platinum-based chemotherapy | GPS | 1.88 (1.25 - 2.84) | 0.002 | NA | NA |
| Meek et al (2010) [31] | UK | 56 | Inoperable | mGPS | ND | < 0.001 | NA | NA |
| Leung et al (2012) [16] | UK | 261 | Inoperable | mGPS 0, 1, 2 | 1.67 (1.28 - 2.19) | < 0.0001 | NA | NA |
| Simmons et al (2015) [32] | UK | 390 | Stage IV NSCLC (N = 288) or ES-SCLC | mGPS 0, 1, 2 | 1.67 (1.40 - 2.00) | < 0.001 | NA | NA |
| Jiang et al (2015) [34] | China | 138 | Stage IIIB or IV CDDP-based chemotherapy | 0 vs. 1 0 vs. 2 |
0.8 (0.4 - 0.9) 0.5 (0.2 - 0.9) |
0.02 | 0.8 (0.5 - 0.9) 0.6 (0.2 - 0.8) |
0.03 |
| Zhu et al (2016) [33] | China | 105 | Inoperable stage IIIB or IV, first-line chemotherapy | mGPS 0, 1, 2 | 1.19 (0.81 - 1.75) | 0.374 | 1.10 (0.79 - 1.53) | 0.579 |
| Lv et al (2017) [30] | China | 266 | Recurrence after resection, systemic chemotherapy | mGPS 0 - 1 vs. 2 | 1.47 (1.15 - 1.88) | 0.002 | NA | NA |
| Our | Japan | 159 | Stage IIIB or IV, Ad, platinum-based | mGPS 0 - 1 vs. 2 | 1.95 (1.20 - 3.16) | < 0.01 | NA | NA |
Ad: adenocarcinoma; CDDP: cisplatin; CI: confidence interval; ES-SCLC: extensive stage small cell lung cancer; GPS: Glasgow prognostic score; HR: hazard ratio; mGPS, modified Glasgow prognostic score; NA: not assessed; ND: not described; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival.